Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Completed · Phase 2

Conditions studied: Marginal Zone Lymphoma

In brief

Zevalin may be an effective therapy for newly diagnosed marginal zone lymphoma (MZL).

Key facts

Study ID
NCT00453102
Run by
University of Miami
People needed
18
Starts
2006-02-01
Expected to finish
2015-02-01
Last updated by the study team
2016-01-01

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.